Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 320 participants.
Also called NCT01646320
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 320 participants
- Sponsor
- Registry
-
NCT01646320 -
2011-006324-20
-
- Other papers using this trial's data
- Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Czechia, Mexico, Poland, Puerto Rico, Romania, Russia, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01646320. Randomized; triple masking; primary purpose treatment. Start 2012-09 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2016-04-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Placebo matching with Dapagliflozin
- Intervention (Drug)
- Saxagliptin
- Intervention (Drug)
- Metformin immediate release (IR)
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct01646320- Content hash
b162d986258e64f313f8e07d621e92bb8a850a61e23684c756e5d5a3d6350bd3